Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ledipasvir + sofosbuvir + GS-9669
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of three direct-acting antiviral agents developed for the treatment of chronic hepatitis C virus (HCV) infection, particularly genotype 1. - **Ledipasvir** is an NS5A inhibitor that blocks replication and assembly of HCV. - **Sofosbuvir** is a nucleotide analog NS5B polymerase inhibitor that acts as a chain terminator to prevent viral RNA synthesis. - **GS-9669** is a non-nucleoside NS5B polymerase inhibitor acting at a distinct allosteric site, further inhibiting HCV replication. This three-drug regimen aims to maximize suppression of HCV replication, accelerate cure rates (sustained virologic response, SVR), and shorten treatment durations. The specific combination has been studied in Phase 2 trials in both treatment-naive and treatment-experienced subjects with cirrhosis. The regimen is administered orally and was shown to be generally well tolerated, with headache and nausea as the most common adverse events[3][4][5].
- Other names
- ledipasvir + sofosbuvir + GS-9669
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))
Beyond the preview
Go deeper on ledipasvir + sofosbuvir + GS-9669.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ledipasvir + sofosbuvir + GS-9669.